23 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product
ARS
j32 8ki07
28 Apr 23
Annual report to shareholders
7:03am
424B4
u1f1kl uyy
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
3dyf02g16qvxm1grtht
19 May 21
Draft registration statement
12:00am
10-K
hkau5i 26n6760dldnk9
11 Mar 21
Annual report
4:19pm
10-Q
iyaqzyz
12 Nov 20
Quarterly report
4:28pm
424B4
n3w1si37
2 Oct 20
Prospectus supplement with pricing info
5:10pm